Table 5 Odds ratios for risk factors associated with lipodystrophy, Myanmar, 2016
Lipodystrophy | Hypertriglyceridemia | |||||
|---|---|---|---|---|---|---|
OR (95% CI) | aOR (95% CI) | p-value | OR (95% CI) | aOR (95% CI) | p-value | |
Sex | ||||||
Female | ref | ref | ref | ref | ||
Male | 1.0 (0.6–1.8) | 0.80 (0.4–1.6) | 0.589 | 1.1 (0.5–2.4) | 0.9 (0.4–2.2) | 0.768 |
Age (years) at ART start | 0.8 (0.8–0.9) | 0.9 (0.8–1.0) | 0.059 | 1.0 (0.9–1.1) | 1.1 (1.0–1.3) | 0.067 |
WHO status at cohort entry | ||||||
1 | ref | ref | ref | ref | ||
2 | 1.7 (0.7–4.0) | 1.2 (0.4–3.1) | 0.729 | 0.6 (0.2–1.8) | 0.5 (0.2–1.5) | 0.213 |
3 | 1.9 (0.9–4.3) | 2.1 (0.8–5.4) | 0.117 | 0.6 (0.2–1.5) | 0.3 (0.1–1.0) | 0.055 |
4 | 0.8 (0.2–3.6) | 0.9 (0.2–5.0) | 0.921 | 0.7 (0.1–3.7) | 0.4 (0.1–2.8) | 0.350 |
Exposure to D4T-based regimen1 | ||||||
No | ref | ref | ref | ref | ||
Yes | 19 (2.5–142) | 11 (1.3–92) | 0.028 | 5.5 (0.7–42) | 8.1 (0.9–73) | 0.061 |
Exposure to AZT-based regimen1 | ||||||
No | ref | ref | ref | ref | ||
Yes | 2.1 (1.1–4.2) | 1.7 (0.6–4.3) | 0.290 | 1.0 (0.4–2.4) | 3.3 (1.0–10.3) | 0.042 |
Exposure to PI-based (LPV) regimen1 | ||||||
No | ref | ref | ref | ref | ||
Yes | 2.0 (1.0–4.1) | 1.3 (0.4–3.8) | 0.645 | 3.7 (1.6–8.3) | 7.7 (2.2–26.8) | 0.001 |
Exposure to EFV-based regimen1 | ||||||
No | ref | ref | ref | ref | ||
Yes | 0.3 (0.2–0.7) | 0.5 (0.2–1.3) | 0.161 | 0.6 (0.3–1.4) | 2.3 (0.7–7.4) | 0.148 |